Skin and soft tissue infections (SSTIs) constitute a major healthcare challenge today, particularly when caused by methicillin- or multi drug-resistant Staphylococcus aureus (MRSA), for which conventional antibiotic therapies are ineffective. Such infections may become lethal in immunocompromised patients, such as primary immunodeficiencies or cancer patients receiving chemotherapy. To fight multi drug-resistant infections, systemic treatment with the antibiotic.
Bausch + Lomb announced that JAMA Ophthalmology has published 10-year results of the ongoing, multicenter, prospective Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study evaluating profiles and trends in antibiotic resistance among common ocular bacterial pathogens across the United States.1 ARMOR is the only ongoing surveillance study of its kind.
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the U.S. launch of intravenous and oral formulations of Baxdela™ (delafloxacin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. With Baxdela, no dosage adjustments are required due to weight, hepatic impairment or mild-moderate renal impairment, there are no food effects, and there is minimal potential for drug interactions.
Market Place
Share
Methicillin News Full Screen View
Share
